The molecular basis of partial penetrance of splicing mutations in cystic fibrosis - PubMed (original) (raw)
The molecular basis of partial penetrance of splicing mutations in cystic fibrosis
N Rave-Harel et al. Am J Hum Genet. 1997 Jan.
Abstract
The splicing variant, 5T allele, in intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene was shown to be associated with partial penetrance of the clinical expression. This splicing variant leads to two possible transcripts: one normal and the other aberrantly spliced that lacks exon 9. The aim of this study was to analyze the molecular basis of the partial penetrance in individuals carrying the 5T allele. We analyzed the level of the correctly spliced RNA transcribed from the 5T allele in nasal and epididymal epithelium and correlated it with disease expression. Semiquantitative nondifferential reverse-transcriptase-PCR showed a considerable variability (6%-37%) in the total level of correctly spliced RNA transcribed from the 5T allele in nasal epithelium from 11 patients. A significant nonlinear correlation (r = .82, P = .002) between the level of the normal CFTR transcripts and the severity of lung disease was shown. No individuals with normal lung function and minimal or no lung disease (FEV1 >80% predicted) had <25% of normal transcripts, and individuals with <15% of normal transcripts did not have FEV1 >80%. The level of normal transcripts in epididymal epithelial cells from four infertile males with congenital bilateral absence of the vas deferens was low (6%-24%). In infertile males with normal lung function the level of correctly spliced transcripts in the nasal epithelium was higher than the level in the epididymal epithelium. These results indicate that there is variability in the efficiency of the splicing mechanism, among different individuals and between different organs of the same individual. This variability provides the molecular basis of the partial penetrance of cystic fibrosis disease in patients carrying the 5T allele.
Similar articles
- The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation.
Chiba-Falek O, Kerem E, Shoshani T, Aviram M, Augarten A, Bentur L, Tal A, Tullis E, Rahat A, Kerem B. Chiba-Falek O, et al. Genomics. 1998 Nov 1;53(3):276-83. doi: 10.1006/geno.1998.5517. Genomics. 1998. PMID: 9799593 - A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations.
Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba-Falek O, Kraemer MR, Simon A, Branski D, Kerem B. Kerem E, et al. Am J Respir Crit Care Med. 1997 Jun;155(6):1914-20. doi: 10.1164/ajrccm.155.6.9196095. Am J Respir Crit Care Med. 1997. PMID: 9196095 - A T3 allele in the CFTR gene exacerbates exon 9 skipping in vas deferens and epididymal cell lines and is associated with Congenital Bilateral Absence of Vas Deferens (CBAVD).
Disset A, Michot C, Harris A, Buratti E, Claustres M, Tuffery-Giraud S. Disset A, et al. Hum Mutat. 2005 Jan;25(1):72-81. doi: 10.1002/humu.20115. Hum Mutat. 2005. PMID: 15580565 - The molecular basis for disease variability in cystic fibrosis.
Kerem B, Kerem E. Kerem B, et al. Eur J Hum Genet. 1996;4(2):65-73. doi: 10.1159/000472174. Eur J Hum Genet. 1996. PMID: 8744024 Review. - Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens.
De Braekeleer M, Férec C. De Braekeleer M, et al. Mol Hum Reprod. 1996 Sep;2(9):669-77. doi: 10.1093/molehr/2.9.669. Mol Hum Reprod. 1996. PMID: 9239681 Review.
Cited by
- Accurate and Automated Genotyping of the CFTR Poly-T/TG Tract with _CFTR_-TIPS.
Ding Q, Hofich CD, Kellogg TB, Kuennen RK, Paxton KN, Thieke SM, Rumilla KM, Hasadsri L. Ding Q, et al. Int J Mol Sci. 2024 Aug 5;25(15):8533. doi: 10.3390/ijms25158533. Int J Mol Sci. 2024. PMID: 39126101 Free PMC article. - All exons are not created equal-exon vulnerability determines the effect of exonic mutations on splicing.
Holm LL, Doktor TK, Flugt KK, Petersen USS, Petersen R, Andresen BS. Holm LL, et al. Nucleic Acids Res. 2024 May 8;52(8):4588-4603. doi: 10.1093/nar/gkae077. Nucleic Acids Res. 2024. PMID: 38324470 Free PMC article. - An intronic RNA element modulates Factor VIII exon-16 splicing.
Tse V, Chacaltana G, Gutierrez M, Forino NM, Jimenez AG, Tao H, Do PH, Oh C, Chary P, Quesada I, Hamrick A, Lee S, Stone MD, Sanford JR. Tse V, et al. Nucleic Acids Res. 2024 Jan 11;52(1):300-315. doi: 10.1093/nar/gkad1034. Nucleic Acids Res. 2024. PMID: 37962303 Free PMC article. - Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup.
Walker LC, Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, Canson DM, Bis-Brewer D, Cass A, Tchourbanov A, Zimmermann H, Byrne AB, Pesaran T, Karam R, Harrison SM, Spurdle AB; ClinGen Sequence Variant Interpretation Working Group. Walker LC, et al. Am J Hum Genet. 2023 Jul 6;110(7):1046-1067. doi: 10.1016/j.ajhg.2023.06.002. Epub 2023 Jun 22. Am J Hum Genet. 2023. PMID: 37352859 Free PMC article. - APPLICATION OF THE ACMG/AMP FRAMEWORK TO CAPTURE EVIDENCE RELEVANT TO PREDICTED AND OBSERVED IMPACT ON SPLICING: RECOMMENDATIONS FROM THE CLINGEN SVI SPLICING SUBGROUP.
Walker LC, de la Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, Canson DM, Bis-Brewer D, Cass A, Tchourbanov A, Zimmermann H, Byrne AB, Pesaran T, Karam R, Harrison S, Spurdle AB. Walker LC, et al. medRxiv [Preprint]. 2023 Feb 26:2023.02.24.23286431. doi: 10.1101/2023.02.24.23286431. medRxiv. 2023. PMID: 36865205 Free PMC article. Updated. Preprint.
References
- Am J Pathol. 1994 May;144(5):906-14 - PubMed
- Am J Hum Genet. 1994 May;54(5):820-30 - PubMed
- Am J Hum Genet. 1995 Jan;56(1):272-7 - PubMed
- Hum Genet. 1995 Feb;95(2):205-11 - PubMed
- Biochemistry. 1979 Nov 27;18(24):5294-9 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical